JUNG, Sang Taek,정상택,CHUN, Kwang-Jin,천광진,HA, Ji Yeon,하지연
申请号：
KRKR2019/001290
公开号：
WO2019/151771A1
申请日:
2019.01.30
申请国别(地区):
KR
年份:
2019
代理人:
摘要：
The present invention relates to a PD-1 variant having improved binding to PD-L1. In addition, the present invention relates to a method for producing and a method for screening for the PD-1 variant. A PD-1 variant of the present invention effectively inhibits binding between wild-type PD-1 and PD-L1, and thus can be expected to have penetration power and an effect of cancer death by immunocytes or a treatment effect on infectious diseases, which are far greater than those of conventional therapeutic agents for immune checkpoint inhibition and, simultaneously, can minimize the possibility of immunogenicity occurrence and, further, can promote the convenience of developing biological pharmaceutical drugs through the implementation of aglycosylation.La présente invention concerne un variant de PD-1 ayant une liaison améliorée à PD-L1. La présente invention concerne également un procédé de production et un procédé de criblage pour le variant de PD-1. Le variant de PD-1 fourni par la présente invention inhibe de manière efficace la liaison entre PD-1 et PD-L1 de type sauvage, et peut ainsi avoir une puissance de pénétration et un effet d'élimination du cancer par immunocytes ou un effet de traitement sur des maladies infectieuses, qui sont beaucoup plus élevés que ceux fournis des agents thérapeutiques classiques pour l'inhibition de points de contrôle immunitaires et, simultanément, peuvent réduire au minimum la possibilité d'apparition d'immunogénicité et, en outre, peuvent favoriser la commodité de développement de médicaments pharmaceutiques biologiques par la mise en oeuvre d'aglycosylation.본 발명은 PD-L1 결합력이 증대된 PD-1 변이체에 관한 것이다. 또한, 본 발명은 상기 PD-1 변이체의 제조방법 및 스크리닝 방법에 관한 것이다. 본 발명의 PD-1 변이체는 야생형 PD-1 및 PD-L1 간 결합을 효과적으로 억제하여 기존의 면역 관문 억제 치료제와 비교하여 월등히 높은 투과력과 면역세포의 암사멸 효과 또는 감염성 질환의 치료효과를 기대할 수 있으며, 동시에 면역원성 발생의 가능성을 최소화할 수 있다. 더불어, 무당화 구현을 통한 생물의약품 개발 편의성을 도모할 수 있다.
